PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2082818
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2082818
The global interventional cardiology devices market is projected to reach USD 42.39 billion by 2031, from USD 31.12 billion in 2026, growing at a CAGR of 6.4% during the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Type, End User, and Region |
| Regions covered | Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa. |
The worldwide interventional cardiology devices market is growing mainly because of factors such as a higher incidence of cardiovascular diseases, a preference for less invasive procedures, and an aging global population. In addition, innovations in medical technology, such as drug-eluting stents, bioresorbable scaffolds, and enhanced imaging with catheter-based techniques, are making procedures safer and more successful. Furthermore, the spread of better healthcare facilities in developing countries, the introduction of reimbursement policies that encourage treatment in developed regions, and higher consumer awareness of heart disease detection and treatment are also contributing to market growth.

"Based on the angioplasty balloon type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market."
The old or normal (plain) angioplasty balloons segment of the angioplasty balloons market is growing due to low cost, general acceptance in clinical practice, and high usage in routine and first-line percutaneous coronary interventions, especially in developing and cost-sensitive healthcare settings. They are frequently used to prepare the lesion for stent placement and in uncomplicated coronary and peripheral procedures, which helps maintain demand. Moreover, their established safety record, user-friendliness, and the wide range of available sizes make them the preferred option in high-volume hospitals, thereby contributing to the continuous growth of the market, even though there have been developments in the technologies for specialty balloons.
"The embolic protection devices segment in the hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."
Cardiovascular and neurovascular interventions, especially transcatheter aortic valve replacement (TAVR), carotid artery stenting, and peripheral vascular procedures, are the main drivers of increased sales of embolic protection devices in the hemodynamic flow alteration device market. These devices, which prevent strokes and distal ischemia that may occur as a side effect of the procedure, have led to more patients being treated and better clinical outcomes. Market growth is supported by technological advancements that yield better filters, more efficient capture, and easier deliverability, as well as by positive clinical evidence and the rising popularity of minimally invasive procedures among the elderly.
"The guidewires segment in the other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market."
Growth in the interventional cardiology devices market's guidewires segment is primarily driven by the rising incidence of surgical interventions involving percutaneous coronary angioplasty, a direct result of the global rise in cardiovascular diseases. Guidewires are among the most essential items for interventional procedures, creating steady demand in hospitals and catheterization labs. Emerging technologies, such as improved torque control, greater flexibility, hydrophilic coatings, and enhanced lesion-crossing ability, have expanded their use in complex and chronic total occlusion procedures. In addition, the growing preference for minimally invasive treatments, expanding healthcare infrastructure in developing countries, and the large number of procedures performed in both diagnostic and therapeutic interventions continue to support the market growth.
"Based on the end user, the hospital segment is expected to grow by the highest CAGR in the interventional cardiology devices market.
Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are performed in hospitals because they offer specialized facilities and sophisticated imaging technologies that support high-quality patient care. Hospitals are well-equipped for both simple and complex procedures. These settings enable cardiologists to apply the latest technologies, including drug-eluting stents, rotational atherectomy, and intravascular ultrasound, to ensure utmost precision and safety for patients.
"The Asia Pacific is expected to grow with the highest CAGR in the interventional cardiology devices market during the forecast period."
The rise in cardiovascular diseases and the growing number of catheter-based heart surgeries performed in hospital settings have been the main drivers of growth in the interventional cardiology devices market. Hospitals are major end users, where complex and high-risk interventions are carried out because of their advanced infrastructure, the presence of skilled interventional cardiologists, and access to hybrid operating rooms and cath labs. The increasing use of minimally invasive techniques, favorable reimbursement for inpatient and outpatient cardiac interventions, and hospitals' ongoing investment in advanced interventional technologies also support their dominance and contribute to market growth.
Key players in the interventional cardiology devices market
Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).
The report analyzes the interventional cardiology devices market and aims to estimate the market size and future growth potential across segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. The report also includes a product portfolio matrix of the interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will provide market leaders and new entrants in this market with the closest available estimates of revenue for the overall interventional cardiology devices market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides information on key market drivers, restraints, challenges, and opportunities.